Article Sidebar

Submitted
12 January 2021
Accepted
12 January 2021
Published
31 March 2020
Download
PDF
Statistic
Read Counter : 813 Download : 658

Main Article Content

Abstract

Patients with advanced heart failure (NYHA FC III and IV heart failure) had positive cardiac troponin levels in previous cohort studies. In heart failure, cardiac troponin T (cTnT) is a biomarker that is sensitive to myocardial damage, especially myocardial necrosis. However, there is still little information regarding changes in cTnT levels during standard therapy. This prospective observational study is aimed at evaluating changes in cTnT levels before and after theadministration of standard therapy and evaluating symptom improvement before and after the administration of standard therapy in patients with severe heart failure. Measurement of cTnT levels and symptom improvement parameters before treatment was carried out on the first day of the inpatient and measurement after therapy was carried out on the last day of the inpatient. Sampling was done by consecutive sampling and found 30 patients in the inpatient room of the SMF Cardiovascular Disease, Dr. Soetomo Hospital, Surabaya during the months of May-July 2017. The results of the study obtained the average cTnT levels before therapy 33.48 + 31.88 pg/ml and the average cTnT levels after therapy 46.32 + 52.68 pg/ml. Based on the statistical difference test with the Wilcoxon sign-ranked test, there was no significant change in cTnT levels (p = 0.318). On the parameter of clinical symptom improvement, there was a significant decrease in pulse, respiratory rate, blood pressure, and mean arterial pressure before and after administration of therapy (p <0.05). There was no change in troponin T levels before and after the administration of therapy meant there was no worsening of myocardial necrosis.

Keywords

Heart failure standard therapy cardiac troponin T myocardial necrosis

Article Details

License

Copyright (c) 2020 Folia Medica Indonesiana

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Indrawijaya, Y. Y. A., Suharjono, S., Aminuddin, M., Retnowati, E., & Rahman, G. M. (2020). Changes on Serum Troponin T Level before and after Taking Standard Therapy Medication in Heart Failure Patients. Folia Medica Indonesiana, 56(1), 4–14. https://doi.org/10.20473/fmi.v56i1.24548
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Cotter, G, Stough, WG, Felker, GM, et al (2005). Acute heart failure: nomenclature, pathophysiology, and outcome measures. In Managing acute decompensated heart failure. USA, Taylor & Francis, p 19-36
  2. Domanski, MJ, Mitchell, GF, Norman, JE (1999). Independent prognostic information provided by Sphygmomanometrically Determined Pulse Pressure and Mean Arterial Pressure in Patients with Left Ventricular Dysfunction. Journal of the American College of Cardiology 33, 951-959
  3. Farre N, Vela E, Cleries M, et al (2011). Real world heart failure epidemiology and outcome: A population-based analysis of 88,195 patients. PLoS ONE 12, 1-13
  4. Ferreira J, Santos M, Almerida S, et al (2014). Clinical study high-sensitivity Troponin T: A biomarker of diuretic response in decompensated heart failure patients. Cardiology Research and Practice, 1-9
  5. Forleo GB, Santini L, Campoli M (2015). Long-term monitoring of respiratory rate in patients with heart failure: Multiparametric Heart Failure Evaluation in Implantable Cardioverter-Defibrillator Patients (MULTITUDE-HF) study. Journal Interventional Cardiac Electrophysiology 43, 135-144
  6. Friedrich EB, Bohm M (2007). Management of end stage heart failure, Heart 93, 626-631
  7. Gaggin HK, Januzzi JL (2015). Cardiac Biomarkers and Heart Failure, American College of Cardiology, 1-14
  8. Gheorghiade M, Abraham WT, Albert NM, et al (2006). Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. American Medical Association 296, 2209-2259
  9. Grodin JL, Tang WHW (2013). Prognostic role of cardiac troponin in heart failure. American college of cardiology, 1-7
  10. Heran BS, Musini VM, Bassett K, et al (2012). Angiotensin receptor blockers for heart failure. Cochrane Database System Review 18, 1-80
  11. Hori M, Okamoto H (2012). Heart rate as a target of treatment of chronic heart failure. Journal of Cardiology 60, 86-90
  12. Hunt SA (2005). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Uptodate the 2001 Guidelines for the Evaluation and Management of Heart Failure). Journal of the American College of Cardiology 46, 1-82
  13. Ishii J, Nomura M, Nakamura Y, et al (2002). Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. American Journal of Cardiology 89, 691-695
  14. Khan MA, Ahmed F, Nyeses L, et al (2013). Atrial fibrillation in heart failure: The sword of Damocles revisited, Word Journal of Cardiology 5, 215-227
  15. Kociol R, Pang P, Gheorgiade MF, et al (2010). Troponin Elevation in Heart Failure. Journal of the American College of Cardiology 56, 1071-1078
  16. Krumholz HM, Merrill, AR, Schone, EM, et al (2009). Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission, Circulation 2, 407-413
  17. Mallick A, Januzzi JL (2015). Biomarkers in Acute heart failure. Revista espanola de Cardiologia 68, 514-525
  18. Manickasavagam S, Meria R, Koerner MM, et al (2009). Management of hypertension in chronic heart failure. Expert Review Cardiovascular Therapy 7, 423-433
  19. Miller WL, Hartman KA, Burrit MF (2009). Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. Journal of the American College of Cardiology 54, 1715-1721
  20. Miller WL (2016). Fluid volume overload and congetion in heart failure: time to reconsider pathophysiology and how volume is assessed. Circulation Heart Failure 9, 1-9
  21. Nohria A, Lewis E, Stevenson LW (2002). Medical management of advanced heart failure. Journal of American Medical Association 287, 628-640
  22. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) (2015). Pedoman tatalaksana gagal jantung. Indonesian Heart Association 1, 1-47
  23. Pfisterer M, Buser P, Rickli H, et al (2009). BNP-guided vs symptom-guided heart failure therapy. the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial. Journal of the American Medical Association 301, 383-392
  24. Ponikowski P, Voors A, Anker S, et al (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal 37, 2129-2200
  25. Roger VL (2013). Epidemiology of heart failure. Circulation 113, 646-659
  26. Singh S, Vebgadakrishnan K, Damodharan J (2015). Clinical profile of cardiac failure and its correlation with lab markers and outcome. International Journal of Scientific Study 3, 145-148
  27. Stoner JD, Bolen JL, Harrison DC (1977). Comparison of dobutamine and dopamine in treatment of severe heart failure, British Heart Journal 39, 536-539
  28. Swedberg K, Cleland J, Dargie H, et al (2005). Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The task force for the diagnosis and treatment of chronic heart failure of the european society of cardiology. European Heart Journal, 26, 1115-1140
  29. Takashio S, Toshiyuki N, Sugano Y (2017). Persistent increase in cardiac troponin T at hospital discharge predicts repeat hospitalization in patients with acute decompesation heart failure. PloS ONE 12, 1-12
  30. Valle R, Aspromonte N, Milani L (2011). Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels. Heart Failure Review 16, 519-529
  31. Wal MHL, Jaarsma T, Veldhuilsen DJ (2005). Non-compliance in patients with heart failure; how can we manage it? The European Jourenal of Heart Failure 7, 5-17
  32. Wang JG, Franklin SS, Fagard R, et al (2005). Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 45, 907-913
  33. Yancy CW, Jessp M, Bozkurt B, et al (2013). 2013 ACCF/AHA guideline for the management of heart failure. Journal of the American College of Cardiology 62, 147-239
  34. Zhao Z, Wang H, Jessup JA, et al (2014). Role of estrogen in diastolic dysfunction. American Journal of Physiology-Heart and Circulatory Physiology 306, 628-640